In a recent study published in the journal Nature , a group of researchers identified brain circuits that can be targeted by glucagon-like peptide-1 (GLP1)-based obesity drugs to promote weight loss without causing adverse side effects. Study: Dissociable hindbrain GLP1R circuits for satiety and aversion . Image Credit: MillaF / Shutterstock A long-standing question concerns the relationship between satiety and nausea, as nausea often leads to appetite loss despite occurring independently of physiological satiety.
This relationship is particularly relevant given the high prevalence of nausea resulting from various medical conditions. Understanding this relationship is crucial given the prevalence of nausea from various conditions and the urgent need for effective weight-loss treatments. With 2.
6 billion people worldwide classified as overweight or obese, the adverse side effects of current weight-loss drugs, especially nausea and vomiting, hinder their efficacy. GLP1 receptor (R) agonists like exenatide, liraglutide, and semaglutide are effective but commonly cause nausea. Further research is needed to develop weight-loss drugs that effectively promote satiety without causing adverse side effects like nausea, thereby improving treatment adherence and efficacy.
The present study used various drugs and reagents , including paraformaldehyde, Triton X-100, and semaglutide from suppliers like Millipore Sigma, Bio-Techne, and Cayman. Viral vectors from Addgene and the Neuroscience .